Drugs / pateclizumab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00888745 | May 2009 → Jun 2010 | rheumatoid arthritis | Genentech, Inc. | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT01225393 | Nov 2010 → Jul 2012 | rheumatoid arthritis | Genentech, Inc. | Completed | Missed primary |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pateclizumab | “Pateclizumab (MLTA3698A) is a humanized mAb against lymphotoxin α (LTα), a transiently expressed cytokine on activated B and T cells (Th1, Th17), which are implicated in...” PMID 22225620 ↗ Jan 20121“Pateclizumab (anti-lymphotoxin- alpha; MLTA3698A) is a humanized monoclonal antibody that blocks and depletes anti-LTα.” PMID 25359150 ↗ Oct 2014 |
| Known as | MLTA3698A | “Pateclizumab (MLTA3698A) is a humanized mAb against lymphotoxin α (LTα), a transiently expressed cytokine on activated B and T cells (Th1, Th17), which are implicated in...” PMID 22225620 ↗ Jan 20121“Pateclizumab (anti-lymphotoxin- alpha; MLTA3698A) is a humanized monoclonal antibody that blocks and depletes anti-LTα.” PMID 25359150 ↗ Oct 2014 |
| Known as | PRO-283698 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743056 ↗ |
| Known as | RG-7416 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743056 ↗ |
| Known as | RG7415 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743056 ↗ |
| Action | Inhibit | “is a humanized monoclonal antibody that blocks and depletes anti-LTα” PMID 25359150 ↗ Oct 2014 |
| Modality | Monoclonal antibody | “Pateclizumab (MLTA3698A) is a humanized mAb against lymphotoxin α (LTα)” PMID 22225620 ↗ Jan 2012 |
| Route | Intravenous | “single and multiple doses of intravenous (IV) or subcutaneous (SC) pateclizumab” PMID 22225620 ↗ Jan 2012 |
| Route | Subcutaneous | “single and multiple doses of intravenous (IV) or subcutaneous (SC) pateclizumab” PMID 22225620 ↗ Jan 2012 |
| Target | LTA | “Pateclizumab (MLTA3698A) is a humanized mAb against lymphotoxin α (LTα)” PMID 22225620 ↗ Jan 2012 |